Stories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Six firms downgraded VRNS on 16 October. The wave has reshaped the consensus, yet options traders and short sellers are both pulling in the same bullish direction, with earnings due on 26 October.
The scale of Thursday's analyst action is the standout fact. Jefferies, TD Cowen, Wells Fargo, DA Davidson, RBC Capital, Piper Sandler, and Rosenblatt all cut their ratings in a single session. Every new target landed at or near $49.75. The Jefferies cut was the sharpest: Joseph Gallo slashed his target from $60 to $49.75, a 17% reduction, and moved to Hold from Buy.
The common thread across the notes is the reported Proofpoint acquisition talks. Analysts worry the news hit during the final weeks of the September quarter, when roughly half of quarterly deals were still open. The SaaS transition, while largely complete at around 89% of ARR, is also cited as a source of near-term execution drag.
Citigroup and Baird moved the other way, both raising targets to $49.75 and $50.00 respectively while holding Neutral ratings. Consensus now sits at Hold, with a mean price target of $51.07, implying roughly 4.8% upside to the current price of $48.72.
Short sellers have been voting with their feet. SI stood at 5.2% of free float as of 15 October, down 19% over the prior week and down 28% over the past month. The lending market remains loose: availability stands at 2,643%, with plenty of shares available to borrow relative to those already lent out.
Options positioning leans the same way. The put-call ratio hit 0.48 on 15 October, 2.4 standard deviations below its 20-day average. That reading has softened slightly to 0.56 as of 16 October, but the direction of travel over the past month is clear: the PCR has fallen from around 0.65 in mid-September to current levels, reflecting a pronounced shift toward call positioning ahead of the print.
ORTEX Alt Data shows retail attention spiked to 2.55 standard deviations above its own 90-day average as of 17 October, measured via Wikipedia views and ORTEX page traffic. This is colour on the noise around the Proofpoint story, not a revenue signal, but it confirms that Varonis is attracting well above-average scrutiny in the week before it reports.
On the institutional side, BlackRock reported holding 12.8 million shares as of 30 September, up 1.48 million shares on its prior filing. No 13D activist is on the register.
ORTEX also forecasts a 65% probability that Varonis is deleted from the FTSE Global Small and MSCI World Small indices, linked to the potential Proofpoint acquisition. Those events, if they occur, are estimated for late June 2027. These are ORTEX forecasts, not confirmed index decisions.
See the live data behind this article on ORTEX.
Open VRNS on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
